What’s Really Happening with GLP-1s? Insights From AI-Enabled RWD

For decades, clinical trials and registries have been the primary methods for generating high-quality evidence on drug and device safety, effectiveness, and access. But they are slow, costly, and often limited in scope. Now, EHR data is redefining what’s possible, enabling faster, more flexible, and broadly representative real-world evidence. This session will explore how linking complete EHR data with closed claims and emerging genomic data is transforming drug and device research.Join us to discover how Truveta Data is delivering insights far ahead of postmarket trial data. We’ll explore findings from published studies using Truveta Data to examine GLP-1 utilization trends, comparative effectiveness for weight loss, access barriers, factors influencing discontinuation and reinitiation, and more.You’ll learn:• How advanced AI is extracting and structuring data from EHRs at scale, enabling research on treatment patterns, medication safety and effectiveness, and factors influencing nonadherence and treatment switching.• What’s possible when clean, complete EHR data from 120M+ patients is seamlessly connected with closed claims for a comprehensive view of real-world patient journeys.• How integrating genomic data with large-scale EHR and claims datasets will open new frontiers for precision medicine and targeted therapies.• How researchers can apply these data to study any drug, disease, or device, accelerating discoveries across therapeutic areas.Truveta Data is the most representative, complete, and timely patient journey data – exceeding FDA standards of data quality, provenance, and audit readiness. All data are accurately linked, expertly de-identified, and immediately available for research. Sponsored by Corporate Partner, Truveta